← Research index  ·  Disorder page  ·  Source YAML

Cross-provider research synthesis

BRAF V600E Mutant NSCLC

MONDO:0005233 Curated 2026-07-04T00:00:00Z 9 harmonized findings
falcon · 36 citations openscientist · 42 citations
Concordant asserts the finding Partial supports a weaker/qualified form Contradictory conflicts with it Silent does not address it

Harmonized findings

BRAF V600E-mutant NSCLC is driven by a somatic, constitutively active class I BRAF kinase that signals as a RAS-independent monomer and drives persistent RAF-MEK-ERK (MAPK) pathway activation, the central oncogenic mechanism of the subtype.

UNANIMOUS INTEGRATED
pathophysiologygenetic_factorgene_function
ProviderStanceScoreEvidence
falcon CONCORDANT 95% BRAFV600E is a constitutively active class I BRAF mutation that drives persistent RAF–MEK–ERK signaling and tumor proliferation/survival.
Falcon states the class I constitutive RAF-MEK-ERK driver mechanism directly.
DOI:10.1038/s41698-024-00552-7
openscientist CONCORDANT 97% It is classified as a Class I BRAF mutation, which signals as a RAS-independent monomer with markedly elevated (approximately 500-fold) kinase activity compared to wild-type BRAF
OpenScientist adds the RAS-independent-monomer detail and quantifies the ~500-fold kinase-activity increase.
PMID:39961465

BRAF V600E occurs in roughly 1-2% of all NSCLC and represents approximately half to two-thirds of BRAF-mutant NSCLC in Western populations.

UNANIMOUS INTEGRATED
epidemiologygenetic_factor
ProviderStanceScoreEvidence
falcon CONCORDANT 90% implying ~1–1.5% of NSCLC are BRAF V600E.
Falcon reports BRAF V600 mutations in ~2% of NSCLC with about half being V600E, implying ~1-1.5% of NSCLC.
DOI:10.1634/theoncologist.2017-0642
openscientist CONCORDANT 92% Approximately 2% of advanced NSCLC cases harbor a BRAF V600E (class I) mutation.
OpenScientist gives the same ~1-2% frequency and adds the Western vs Asian V600E fraction (~66% vs ~25%).
PMID:40172088

The subtype presents almost exclusively as adenocarcinoma and is enriched for never-smokers, with a slight female predominance relative to unselected NSCLC.

MAJORITY INTEGRATED
phenotypeepidemiology
ProviderStanceScoreEvidence
falcon PARTIAL 55% predominantly adenocarcinoma (>85%).
Falcon supports adenocarcinoma predominance (>85%) and states BRAFV600E is less smoking-associated, but does not quantify never-smoker fraction and calls the female enrichment inconsistent across studies.
DOI:10.1038/s41698-024-00552-7
openscientist CONCORDANT 92% 50.3 % were female, 30.2 % were never smokers, 95.1 % had adenocarcinoma, and 78.2 % had a PDL1 ≥ 1 %. The median age was 68.3 years.
OpenScientist quantifies the demographic profile from the French BLaDE cohort (>95% adenocarcinoma, ~30% never-smokers, slight female predominance).
PMID:39616778

Dabrafenib plus trametinib (BRAF plus MEK inhibition) is an established, guideline-supported targeted therapy producing objective response rates around 63-75% in BRAF V600E-mutant metastatic NSCLC.

UNANIMOUS INTEGRATED
treatment
ProviderStanceScoreEvidence
falcon CONCORDANT 92% FDA approval summary confirms similar magnitude: ORR 63% (previously treated) and 61% (treatment-naïve), with majority of responses durable ≥6 months.
Falcon reports the pivotal dabrafenib+trametinib phase II ORRs and FDA-approval efficacy magnitude.
DOI:10.1634/theoncologist.2017-0642
openscientist CONCORDANT 90% The ORR by both central and investigator assessment was 75% [95% confidence interval (CI): 50.9-91.3%].
OpenScientist corroborates D+T efficacy with the Chinese phase II ORR of 75% and real-world PFS data.
PMID:39830765

Encorafenib plus binimetinib (PHAROS trial) is a second approved BRAF/MEK combination with treatment-naive ORR of 75% and previously-treated ORR of 46%, and mature follow-up shows the longest reported median OS in this setting.

UNANIMOUS INTEGRATED
treatmentprognosis
ProviderStanceScoreEvidence
falcon CONCORDANT 80% ORR by IRR was 75% (95% CI, 62 to 85) in treatment-naïve and 46% (95% CI, 30 to 63) in previously treated patients.
Falcon reports the PHAROS ORRs but (predating mature follow-up) records PFS/OS as not estimable rather than the later survival readout.
DOI:10.1200/jco.23.00774
openscientist CONCORDANT 95% mOS was 47.6 months (95% CI, 31.3 to not estimable); 4-year OS probability was 49% (95% CI, 35 to 62).
OpenScientist adds the mature PHAROS survival data (median OS 47.6 months, 4-year OS 49%) and a MAIC suggesting E+B may outperform D+T.
PMID:41109959

Acquired resistance to BRAF/MEK-targeted therapy arises chiefly through MAPK pathway reactivation (secondary RAS/MEK mutations, BRAF amplification) and bypass-pathway activation, detectable via ctDNA/single-cell profiling.

UNANIMOUS INTEGRATED
pathophysiologytreatment
ProviderStanceScoreEvidence
falcon CONCORDANT 85% MAPK-dependent, related to the reactivation of the MAPK pathway
Falcon characterizes resistance as MAPK-dependent reactivation plus MAPK-independent alterations, with recurrent BRAF splice variants, amplification, and NRAS/KRAS/MEK changes.
DOI:10.1038/s41416-023-02535-0
openscientist CONCORDANT 88% Serial ctDNA analysis can detect MAPK pathway reactivation mutations, bypass pathway alterations, and emerging co-mutations that may predict treatment failure.
OpenScientist matches the MAPK-reactivation/bypass framework and adds lineage transformation (NKX2-1 loss) and acquired BRAF V600E after EGFR-TKI therapy.
PMID:32859654

BRAF V600E-mutant NSCLC carries a strikingly high thromboembolism risk, with a reported 1-year cumulative incidence of 43% including cancer-related stroke and venous thromboembolism.

SINGLE LEAD
phenotypecomorbidity
ProviderStanceScoreEvidence
openscientist CONCORDANT 90% five developed a total of seven thromboembolic events, showing a 1-year cumulative incidence of 43% (95% confidence interval=11-72%).
OpenScientist highlights thromboembolism as a distinctive phenotype with a 43% 1-year cumulative incidence and management implications.
PMID:36697098
falcon SILENT —
Falcon's report does not address thromboembolism risk in BRAF V600E NSCLC.

BRAF V600E frequently expresses PD-L1 and immune checkpoint inhibitors show clinical activity, but targeted therapy is prioritized and reported ICI-benefit evidence is heterogeneous.

MAJORITY LEAD
treatmentpathophysiology
ProviderStanceScoreEvidence
falcon PARTIAL 50% Immune checkpoint inhibitors are used in BRAF-mutant NSCLC, but retrospective evidence is mixed; targeted therapy is often prioritized for BRAF V600E
Falcon notes ICIs are used but retrospective evidence is mixed and targeted therapy is generally prioritized, without quantifying PD-L1 expression.
DOI:10.3389/fonc.2024.1353491
openscientist CONCORDANT 80% High PD-L1 expression (~78% PD-L1 ≥1%) suggests an inflamed tumor microenvironment
OpenScientist quantifies PD-L1 positivity (~78% ≥1%) and cites real-world data showing no detriment from PD-(L)1 inhibitors relative to driver-negative NSCLC.
PMID:39616778

Genetically engineered mouse models expressing lung-restricted BRAF V600E recapitulate MAPK-driven lung adenocarcinoma and demonstrate that cooperating events (e.g. TP53 loss) are needed for progression beyond growth-arrested lesions.

UNANIMOUS LEAD
pathophysiologygenetic_factor
ProviderStanceScoreEvidence
falcon CONCORDANT 85% TP53 silencing bypasses growth arrest
Falcon cites GEMM evidence that BRAF V600E induces MAPK-dependent lung tumors and that TP53 silencing bypasses the senescence-like arrest to enable progression.
DOI:10.1158/0008-5472.can-14-3701, DOI:10.1158/0008-5472.can-06-4592
openscientist CONCORDANT 85% Mouse GEMMs recapitulate key features of human BRAF V600E NSCLC including adenocarcinoma histology, MAPK pathway activation, and response to BRAF/MEK inhibitors
OpenScientist agrees GEMMs recapitulate the disease and adds cooperating-lesion models (NKX2-1 loss, PI3K activation, kinase-inactive alleles).
PMID:28783725

Narrative

Overview

Both providers frame BRAF V600E-mutant NSCLC as a rare (~1-2% of NSCLC), molecularly defined, actionable lung adenocarcinoma subtype in which a somatic class I BRAF mutation constitutively activates the MAPK pathway independent of upstream RAS, with combined BRAF plus MEK inhibition as the central targeted treatment strategy. Falcon is treatment-landscape and pathophysiology focused; OpenScientist is broader and more recent, spanning epidemiology, diagnostics, prognosis, resistance, comorbidity, and model organisms.

Agreement

The reports agree on the core driver biology (constitutive, RAS-independent class I BRAF/MAPK signaling), the ~1-2% NSCLC frequency with V600E as roughly half of BRAF mutations, adenocarcinoma predominance and never-smoker enrichment, the two approved BRAF/MEK combinations (dabrafenib+trametinib and encorafenib+binimetinib/PHAROS) with ORRs around 63-75%, MAPK-reactivation and bypass signaling as the dominant resistance routes, the requirement for broad molecular profiling, and GEMM recapitulation of MAPK-driven lung adenocarcinoma.

Divergence

Divergence is largely coverage and recency rather than contradiction. OpenScientist adds the mature PHAROS survival readout (median OS 47.6 months, 4-year OS 49%) and a MAIC suggesting encorafenib+binimetinib may outperform dabrafenib+trametinib, quantifies the demographic profile and PD-L1 positivity (~78% ≥1%), and uniquely reports the high thromboembolism risk (43% 1-year incidence), co-mutation prognostic effects, ctDNA diagnostics, and NKX2-1-loss lineage transformation. Falcon predates the mature PHAROS follow-up (recording PFS/OS as not estimable), is more cautious on immunotherapy (retrospective evidence "mixed"), and gives a lower adenocarcinoma fraction (>85% vs >95%); these are quantitative/recency differences, not conflicts.

Integration

Integrated into kb/disorders/BRAF_V600E_Mutant_NSCLC.yaml: the overview and treatment section include encorafenib plus binimetinib as a PHAROS-supported BRAF/MEK option; the resistance node was expanded to MAPK reactivation, bypass PI3K-AKT-MET signaling, histologic transformation, and acquired BRAF V600E after EGFR-TKI therapy; a BRAF HGNC gene annotation was added; and reference provenance for both providers was backfilled.

Not integrated (leads)

Treatment-ranking claims from the indirect (MAIC) comparison, detailed thromboembolism management, the PD-L1/immunotherapy sequencing context, and proposed adjuvant/sequencing trials were retained as research leads rather than promoted to curated disease mechanisms.

Cross-provider synthesis comparing falcon (treatment/pathophysiology focused) and openscientist (comprehensive, 15-domain) deep-research reports for BRAF V600E-mutant NSCLC. No direct contradictions were found; divergence is coverage and recency (mature PHAROS survival, thromboembolism, PD-L1/immunotherapy, co-mutations, ctDNA) plus minor quantitative differences (adenocarcinoma >85% vs >95%). best_matching_text values are verbatim excerpts from the cited report files; literature evidence snippets are intentionally left for the disorder-YAML curation pipeline.